Form 8-K - Current report:
SEC Accession No. 0001493152-24-039652
Filing Date
2024-10-07
Accepted
2024-10-07 08:45:29
Documents
16
Period of Report
2024-10-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44416
2 ex99-1.htm EX-99.1 20367
3 ex99-1_001.jpg GRAPHIC 2419
  Complete submission text file 0001493152-24-039652.txt   303918

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20241007.xsd EX-101.SCH 3967
5 XBRL DEFINITION FILE bfri-20241007_def.xml EX-101.DEF 30391
6 XBRL LABEL FILE bfri-20241007_lab.xml EX-101.LAB 37210
7 XBRL PRESENTATION FILE bfri-20241007_pre.xml EX-101.PRE 27410
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6644
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 241356258
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)